Claims for Patent: 9,156,906

Summary for Patent: 9,156,906

Title:	Glycopeptides and methods of making and using them
Abstract:	In one embodiment, the invention provides glycopeptides (or carbohydrate-peptide conjugates) comprising TACAs that direct against (e.g., bind specifically to) cytotoxic T lymphocytes (CTLs) or helper T cells for, e.g., CTL- or T-helper-based immunotherapy of carcinomas, and methods for making and using the glycopeptides of the invention. In one embodiment, the invention provides novel glycopeptides comprising tumor-derived carbohydrate or tumor-derived epitopes that specifically bind to major histocompatibility (MHC) class I molecules on cytotoxic T lymphocytes (CTLs) or MHC molecules on helper T cells, and methods for using same, e.g., as a vaccine, including a pan-cancer vaccine.
Inventor(s):	Franco; Alessandra (La Jolla, CA)
Assignee:	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
Application Number:	12/918,155
Patent Claims:	1. An isolated or synthetic glycopeptide or glycoconjugate consisting of: at least one carbohydrate moiety conjugated or linked to a peptide consisting of: TABLE-US-00015 FLFPDTRAV, (SEQ ID NO: 2) or FLFPDTRYV; (SEQ ID NO: 3) or FLPDTRFYV; (SEQ ID NO: 1) wherein the at least one carbohydrate moiety is a .alpha.-Gal-[1->3]-.beta.-GaINAc or a N-Acetylgalactosamine (GaINAc, 2-Acetamido-2-deoxy-D-galactopyranose or N-Acetyl -D-galactosamine). 2. A composition comprising one or more glycopeptides or glycoconjugates of claim 1. 3. A pharmaceutical composition or formulation comprising: (a) one or more glycopeptides or glycoconjugates of claim 1 and a pharmaceutically acceptable excipient; or (b) the pharmaceutical composition of (a), wherein the pharmaceutical composition is formulated for administration via a parenteral route comprising or consisting of a subcutaneous, an intravenous (IV), an intradermal, an intramuscular, an intraperitoneal, an intranasal, a transdermal or a buccal route. 4. A liposome comprising one or more glycopeptides or glycoconjugates of claim 1. 5. A nanoparticle comprising one or more glycopeptides or glycoconjugates of claim 1. 6. A cancer vaccine comprising: one or more glycopeptides or glycoconjugates of claim 1. 7. The glycopeptide or glycoconjugate of claim 1, further comprising a second carbohydrate moiety, wherein the first carbohydrate moiety consists of a .alpha.-Gal-[1->3]-.beta.-GaINAc or a N-Acetylgalactosamine, and a second carbohydrate moiety comprises or consists of a .beta.-D-glucose, a .beta.-D-galactose, a .beta.-D-mannose, an .alpha.-L-Fucose, an N-Acetylglucosamine (N-Acetyl-D-Glucosamine, or GIcNAc, or NAG), an aminoglycoside or amino hexose sugar, an N-Acetylneuraminic acid (Neu5Ac or NANA), a sialic acid, a Neuraminic acid (5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulosonic acid), a xylose or a pentose sugar. 8. The glycopeptide or glycoconjugate of claim 1, wherein the at least one carbohydrate moiety is conjugated or linked to the peptide: (a) at an amino acid residue central to the peptide, or (b) at an amino acid residue that is not involved in the peptide's binding to an MHC polypeptide. 9. The glycopeptide or glycoconjugate of claim 1, wherein the at least one carbohydrate moiety is conjugated or linked to the peptide: (a) at no amino acid residue within two residues of the amino terminal end or carboxy terminal end of the peptide, or (b) at least three amino acid residues in from either the amino terminal or carboxy terminal end of the peptide. 10. The glycopeptide or glycoconjugate of claim 1, further comprising a second carbohydrate moiety consisting of a monosaccharide, a disaccharide, a trisaccharide or a polysaccharide. 11. A glycopeptide or glycoconjugate consisting of: TABLE-US-00016 FLPD(X-T) RFYV (FLPDTRFYV is SEQ ID NO: 1), FLFPD(X-T) RAV (FLFPDTRAV is SEQ ID NO: 2), or FLFPD(X-T) RYV (FLFPDTRYV is SEQ ID NO: 3), wherein X consists of an .beta.-Gal-[1->3]-.beta.-GaINAc or a N-Acetylgalactosamine. 12. The glycopeptide or glycoconjugate of claim 1, wherein the peptide, or at least one amino acid in the peptide, comprises or consists of a peptidomimetic. 13. The glycopeptide or glycoconjugate of claim 1, wherein the peptide comprises or consists of an isolated, synthetic or recombinantly generated peptide or amino acid. 14. The glycopeptide or glycoconjugate of claim 10, wherein the second carbohydrate moiety is mono- or poly- sialylated, or not sialated. 15. A The vaccine comprising a peptide that: (a) comprises an FLFPDTRAV (SEQ ID NO:2), FLFPDTRYV (SEQ ID NO:3) or FLPDTRFYV (SEQ ID NO:1); or (b) consists of a mixture of an FLFPDTRAV (SEQ ID NO:2), FLFPDTRYV (SEQ ID NO:3) or FLPDTRFYV (SEQ ID NO:1). 16. The vaccine of claim 15, further comprising an adjuvant. 17. The vaccine of claim 15, further comprising a non-specific immuno-stimulator, or a granulocyte-macrophage colony-stimulating factor polypeptide; or a sargramostim. 18. The vaccine of claim 15, wherein the vaccine is formulated for administration parentally or orally, or systemically or topically, or the vaccine is formulated for administration via a parenteral route or via a route comprising a subcutaneous, an intramuscular, an intravenous (IV), an intradermal, an intramuscular, an intraperitoneal, an intranasal, an intradermal, a transdermal or a buccal route, or the vaccine is formulated for administration parenterally by bolus injection or by gradual perfusion over time, or the vaccine is formulated for administration by an oral or a topical route. 19. A liposome comprising the vaccine of claim 15. 20. The vaccine of claim 15, formulated as: a sterile solution for injection; a powder; a lyophilized or a freeze-dried composition; a liquid; an emulsion; a lyophilized powder; a spray; a cream; a lotion; a controlled release formulation; a tablet; a pill; a gel; a patch; in an implant or in a spray; an aqueous or a non-aqueous isotonic sterile injection solution; or an aqueous or a non-aqueous sterile suspension. 21. The glycopeptide or glycoconjugate of claim 10, wherein the second carbohydrate moiety consists of at least one tumor-associated carbohydrate antigen (TACA), or at least one tumor-derived carbohydrate. 22. The vaccine of claim 16, wherein the adjuvant comprises: an incomplete Freund's adjuvant (IFA); an alum; an aluminum phosphate; an aluminum hydroxide; a squalene; a complete Freund's adjuvant (CFA), a levamisole; a muramyl dipeptide (MDP); a monophosphoryl lipid (MPL); a monophosphoryl lipid A (MPLA); a glycosylceramide, a triacyl lipid A; an oil in water emulsion comprising a monophosphoryl lipid A; a threonyl-MDP in an oil-in-water (o/w) emulsion vehicle; a pluronic L121 or a poloxamer 401; a mucosal adjuvant comprising a detoxified mutant A subunit of a cholera toxin (CT); an E. coli heat labile toxin (LT1 or LT2); or, any combination thereof. 23. The isolated or synthetic glycopeptide or glycoconjugate of claim 1, wherein the peptide conjugated or linked to the at least one carbohydrate moiety consists of FLFPDTRAV (SEQ ID NO:2). 24. The isolated or synthetic glycopeptide or glycoconjugate of claim 1, wherein the peptide conjugated or linked to the at least one carbohydrate moiety consists of: FLFPDTRYV (SEQ ID NO:3). 25. The isolated or synthetic glycopeptide or glycoconjugate of claim 1, wherein the peptide conjugated or linked to the at least one carbohydrate moiety consists of: FLPDTRFYV (SEQ ID NO:1). 26. The isolated or synthetic glycopeptide or glycoconjugate of claim 1, wherein the at least one carbohydrate moiety is a .alpha.-Gal-[1->3].beta.-GaINAc. 27. The isolated or synthetic glycopeptide or glycoconjugate of claim 1, wherein the at least one carbohydrate moiety is an N-Acetylgalactosamine (GaINAc, 2-Acetamido-2-deoxy-D-galactopyranose or N-Acetyl-D-galactosamine). 28. The glycopeptide or glycoconjugate of claim 11, wherein the glycopeptide or glycoconjugate consists of FLPD(X-T) RFYV and wherein X consists of an .alpha.-Gal-[1->3]-.beta.-GaINAc or a N-Acetylgalactosamine. 29. The glycopeptide or glycoconjugate of claim 11, wherein the glycopeptide or glycoconjugate consists of FLFPD(X-T)RAV and wherein X consists of an .beta.-Gal-[1->3]-.beta.-GaINAc or a N-Acetylgalactosamine. 30. The glycopeptide or glycoconjugate of claim 11, wherein the glycopeptide or glycoconjugate consists of FLFPD(X-T)RYV, and wherein X consists of an .alpha.-Gal-[1->3]-.beta.-GaINAc or a N-Acetylgalactosamine. 31. The glycopeptide or glycoconjugate of claim 11, further comprising a second carbohydrate moiety consisting of a monosaccharide, a disaccharide, a trisaccharide or a polysaccharide.

Details for Patent 9,156,906

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Partner Therapeutics, Inc.	LEUKINE	sargramostim	For Injection	103362	03/05/1991		2028-02-26
Partner Therapeutics, Inc.	LEUKINE	sargramostim	Injection	103362	03/05/1991		2028-02-26